|
|
|
24.03.26 - 21:48
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 24.03.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.
ISIN Name
CA4013392051 GUARDIAN CAPITAL GRP
CA4013393042 GUARDIAN CAP. GRP A
FR0010907956 CARMAT EO -,04
LU0934195610 ROB.GL.T.R.BD F.DH EO
NO0013671115 INTL PETROL 25/30
US30063P1057 EXACT SCIEN. DL-,01
US5834352016 STEAKHOLDER F.NEW ADR/100
US68237Q2030 ONCONETIX INC.
US98386D3070 XTL BIOPHARMA. ADR 100
XS3307259237 IBERDROLA FINANZAS S.A....
|
|
|
29.10.25 - 07:36
|
CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025) (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces postponing the publication of its 2025 interim financial report (six months ended June 30, 2025).
Reminder on the ongoing receivership procedure
CARMAT has been under receivership procedure since July 1, 2025.
During a hearing on September 30, 2025, the Versailles Economic Court1 (the "Court") had acknowledged that the only take-over-bid within the context of a sales plan which had been received, had lapsed. Given this, the judiciary administrator had submitted to the Court a request aiming at converting the receivership into a liquidation procedure, which was reviewed by the Court during a hearing held on October 14, 2025. During this hearing, the Court decided to postpone the review of this ...
|
|
|
25.09.25 - 14:39
|
XFRA: CXT: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CARMAT EO -,04 CXT FR0010907956 BAW/UFN...
|
|
|
|
|
21.08.25 - 09:12
|
XFRA: CXT: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CARMAT EO -,04 CXT FR0010907956
AB/FROM ONWARDS 21.08.2025 09:02 CET...
|
|
|
14.08.25 - 08:12
|
XFRA: CXT: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CARMAT EO -,04 CXT FR0010907956 BAW/UFN...
|
|
|
|
|
04.08.25 - 09:09
|
XFRA: CXT: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CARMAT EO -,04 CXT FR0010907956
AB/FROM ONWARDS 04.08.2025 09:00 CET...
|
|
|
30.07.25 - 08:24
|
XFRA: CXT: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CARMAT EO -,04 CXT FR0010907956 BAW/UFN...
|
|
|
|
|
02.07.25 - 11:31
|
XFRA: CXT: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CARMAT EO -,04 CXT FR0010907956
AB/FROM ONWARDS 02.07.2025 11:22 CET...
|
|
|
30.06.25 - 10:15
|
XFRA: CXT: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CARMAT EO -,04 CXT FR0010907956 BAW/UFN...
|
|
|
|
|
20.06.25 - 19:12
|
In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities (Business Wire)
|
|
|
Risk of insolvency as early as end of June 2025
Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO's message,
click herePARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission.
Critical financial situation and risk of insolvency at the end of June 2025
In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025.
The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, ...
|
|
|
09.04.25 - 17:51
|
CARMAT Delivers Q1 2025 Results in Line With Its Objectives (Business Wire)
|
|
|
Quarterly sales of €2.4m - multiplied by 2.4 vs Q1 2024
EFICAS clinical trial - recruitment 94% complete
2 scientific publications - a strong driver of Aeson® adoption
Final stage of discussions with the FDA with a view to resume the EFS study in the United States shortly
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (Paris:ALCAR):
Videoconference in English and French this evening.
To join, please register by clicking on one of the following links:
Videoconference in French at 6:00 pm CEST
-
Videoconference in English at 8:00 pm CEST
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today presents its achievements for the first quarter of 2025 and outlook.
Stéphane Piat, Chief Executive Officer of CARMAT, stated: "We have delivered a solid first quarter, in line with our objectives.
The beginning...
|
|
|
27.03.25 - 07:06
|
CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), announces the implementation of a flexible equity financing line with IRIS Capital Investment (“IRIS”), for a maximum of 9,000,000 shares (i.e., approximately 15% of its current share capital), over a 24-month period.
Stéphane Piat, Chief Executive Officer of CARMAT, comments: "I am very pleased with the implementation of this financing line with IRIS Capital Investment, which, based on our current share price, provides us with a potential total financing amount of approximately €7.9 million over the next 24 months, and thus offers substantial room for manoeuvre that we can start benefitting from immediately. In parallel, we are actively working on securing additional funding to ensure the long-term develop...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
